[Federal Register Volume 81, Number 222 (Thursday, November 17, 2016)]
[Notices]
[Pages 81150-81151]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27613]


-----------------------------------------------------------------------

 DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing and/or 
Co-Development

AGENCY: National Institutes of Health. HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. to achieve expeditious commercialization of results of federally-
funded research and development. Foreign patent applications are filed 
on selected inventions to extend market coverage for companies and may 
also be available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Gene Signature Predictive of Hepatocellular 
Carcinoma Response to Transcatheter Arterial Chemoembolization (TACE).
    Keywords: Diagnostic, Biomarker, Prognostic, Hepatocellular 
Carcinoma, Patient Stratification, TACE, HCC.
    Description of Technology: Hepatocellular Carcinoma (HCC) is one of 
the most common cancers worldwide with largely unfavorable outcomes due 
to a lack of effective treatment options for patients in the later 
state of disease. The gold standard of care for HCC patients with 
intermediate to locally advanced tumors is transcatheter arterial 
chemoembolization (TACE), a procedure whereby the tumor is targeted 
both with local chemotherapy and restriction of local blood supply. 
TACE procedures are often not effective, however, and a need exists to 
identify patients that will respond to TACE.
    Scientists in NCI's Laboratory of Human Carcinogenesis have 
identified a 14-gene signature that is predictive of response to TACE. 
The ``TACE Navigator Gene Signature Assay,'' based on a Nanostring 
Technologies platform, is useful in identifying those HCC patients, 
prior to treatment, who will respond to and have the greatest survival 
benefit following TACE. The signature can also identify patients who 
need additional/alternative therapeutic modalities.
    This invention is owned by an agency of the U.S. Government and is 
available for licensing and/or co-development in the U.S., in 
accordance with 35 U.S.C. 209 and 37 CFR part 404, to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

[[Page 81151]]

    Potential Commercial Applications:

 Prognostic test for HCC patient response to TACE procedure
 Companion diagnostic for TACE procedure

    Value Proposition:

 First in class prognostic diagnostic for frontline therapy in 
highly prevalent HCC

    Development Stage: Basic (Target ID).
    Inventor(s): Xin Wei Wang, Ph.D. and Valerie Miller, Ph.D. (NCI).
    Intellectual Property:

HHS Reference No. E-101-2016
U.S. Provisional Application 62/292,789 (HHS Reference No. E-101-2016/
0-US-01) filed February 8, 2016 entitled ``Gene Signature Predictive of 
Hepatocellular Carcinoma Response to Transcatheter Arterial 
Chemoembolization (TACE)''

    Related Technologies: NIH Reference No. E-024-2009 entitled ``Gene 
Signature for Predicting Solid Tumors Patient Response''.
    Collaboration Opportunity: Researchers at the NCI seek licensing 
and/or co-development research collaborations for the commercialization 
of a companion diagnostic for HCC patients undergoing TACE procedures.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].

    Dated: November 8, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-27613 Filed 11-16-16; 8:45 am]
 BILLING CODE 4140-01-P